Production (Stage)
Amylyx Pharmaceuticals, Inc.
AMLX
$5.31
-$0.05-0.93%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -259.86% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -259.86% | |||
| Cost of Revenue | 266.17% | -122.85% | |||
| Gross Profit | -274.91% | 121.87% | |||
| SG&A Expenses | -8.26% | -4.10% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -5.47% | -47.44% | |||
| Operating Income | 7.01% | 46.27% | |||
| Income Before Tax | 5.96% | 47.48% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 4.37% | 48.36% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 4.37% | 48.36% | |||
| EBIT | 7.01% | 46.27% | |||
| EBITDA | 7.03% | 46.32% | |||
| EPS Basic | 23.46% | 48.73% | |||
| Normalized Basic EPS | 40.16% | 34.41% | |||
| EPS Diluted | 23.46% | 48.84% | |||
| Normalized Diluted EPS | 40.16% | 34.41% | |||
| Average Basic Shares Outstanding | 24.93% | 0.74% | |||
| Average Diluted Shares Outstanding | 24.93% | 0.74% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||